$5.8 mil last Q estimated expenses $1.8 mil leaves $4mil PLUS Q revenue 0.7 , 0.8 , 0,9 , ???? mil "Interesting indeed"
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%